Pharmalink strenthens Managing Team

Pharmalink strenthens Managing Team

21.11.2012 - Pharmalink AB has appointed Dr Heather Cook as Director of Regulatory Affairs and Marek Poszepczynski (Photo) as Director of Business Development.

Heather Cook brings more than 15 years of experience within the pharmaceutical industry to the the Swedish specialty pharma company. She cames from H. Lundbeck A/S, where she headed up its regulatory development projects department. Prior to her time with Lundbeck, Dr Cook served at AstraZeneca as its global regulatory affairs director for oncology and a number of other senior roles, including scientific director for neuroscience and infection.Marek Poszepczynski joins Pharmalink after a career spanning 10 years and combining financial and business development experience. Before joining Pharmalink, he arrives at the company from analysts Handelsbanken, where he covered European and Swedish biotechnology stocks. Prior to Handelsbanken, Poszepczynski was Vice President of Business Development at Karolinska Development.

Picture credit: Lenita Gahlin

11.05.2012 Swedish vaccine adjuvant company Isconova AB (Uppsala) has appointed a new CEO. Sven Andréasson took over from Russel Greig, who in turn assumed Ulf Tossman's post as the firm's Chairman of the Board.

Andréasson comes in from Beta-Cell NV (Brussels) and brings in nine years of experience as CEO of Active Biotech AB. Isconova wants to move forward with key clinical studies, strengthen corporate development activities, and enhance revenues from its saponine-based Matrix technology. In 2011, it had vaccine sales of a7.7m, –35.8% less than in 2010. 

22.06.2012 In June, Ireland's Shire plc (Dublin) appointed a new Chief of Business Developer and Global Head of Human Resources. David Colpman, currently Senior Vice President, will take over that responsibility from Barbara Deptula, Shire's Executive Vice President and Chief Corporate Development Officer, who will retire at the end of June.

Colpman, who has been with Shire for 12 years, brings in extensive experience in dealmaking. Prior to Shire, he worked at Glaxo Wellcome, Novo Nordisk and Boots Pharmaceuticals in a variety of business development and commercial roles. He started his industry career at ICI (now AstraZeneca) in formulation and manufacturing. Ann Judge (not pictured), Senior Vice President of Shire’s global Human Resources (HR) team, has also joined the Shire Leadership

26.06.2012 Swiss Molecular Partners AG (Zurich­-Schlieren) has appointed hematologist Lisa Rojk­jaer as its new Chief Medical Officer. Rojk­jaer, who comes in from German antibody specialist MorphoSys AG, has a track record of 10 years in bio­pharmaceutical drug development.

She will be heading up all clinical activities at Molecular Partners. Prior to her post as Vice President and Head of Clinical Development at Morphosys, she held a variety of senior positions in clinical development and medical affairs at Novartis and Novo Nordisk.

25.06.2012 Swiss Cytos Biotechnology Ltd. (Schlieren) has nominated the former CEO of Micromet Inc., Christian Itin, as its Non-executive Director. The biologist resigned from his former post after selling the firm for US$1.16bn in cash to Amgen.

Itin spent 13 years with Micro­met. In 1999, Itin also co-founded Zyomyx Inc., a protein chip company based in the US.

09.07.2012 InDex Pharmaceuticals (Stockholm) has added Stig Løkke Pedersen to its board. The former VP Commercial Operations at H. Lundbeck A/S brings in 25 years of leadership experience and networking in the biotech and pharmaceutical industries.

Pedersen joined Lundbeck in 1992 as CBO, and was selected to join its corporate senior management in 1998. There he served as Executive Vice President from 2003-2011. Pedersen is a partner at Executive Capital A/S and also serves as the Chairman of the Board of Directors at Chemo-metec A/S and Nuevolution A/S.

05.07.2012 Swedish Microbiology specialist Medivir AB has appointed Henric Juserius to head the company's commercial activities. The former Commercial Director (Nordic region) of Actelion Pharmaceuticals will have overall responsibility for the firm's marketing and sales.

His main task will be to prepare the commercial launch of Medivir's Phase III product TMC435, which is being co-developed with Janssen Pharma-ceuticals for hepatitis C. 

20.06.2012 Andrew Bulpin took over Merck-Millipore‘s Process Solutions Business Unit. The chemist – who previously served as Head of Global Pharmaceutical Chemicals Solutions Sales – succeeds the retired Jean-Paul Mangeolle.

Bulpin joined Millipore in 2006 as a Vice President for the firm's Upstream Processing Business Unit. In January 2012, he assumed leadership of the company's Services and Solutions Business Department. Bulpin was appointed to his current position following the company's acquisition by Merck. 

12.07.2012 In June, French Trophos SA appointed Christine Placet as its chief executive officer. She becomes CEO under a previously defined internal succession plan designed to provide continuity for Trophos, to bring the company's ongoing programmess to a successful conclusion and to seek strategic partnerships for its advanced clinical development drug candidates.

 From 2004, Placet was CFO of the clinical stage pharmaceutical company developing innovative therapeutics for indications with under-served needs in neurology and cardiology. She has over 25 years' experience in a variety of areas of finance and business management. Prior to joining Trophos, she was CFO in a number of growing companies and start-ups in various industries, and worked as an auditor for eight years for Ernst & Young. She has a graduate diploma in financial accounting (DESCF) and a business school diploma from Sup de Co Marseille (DESCAF). Damian Marron, previously CEO, has moved to the biopharmaceutical Company Cytheris SA.

18.07.2012 Ark Therapeutics Group (London) has appointed Dr David Venables as its new CEO from the beginning of August.

Since joining the Board in April of this year, he has focused on the development of Ark's viral development and manufacturing capabilities based in Kuopio, Finland. Martyn Williams, who joined the Company in October 1998 as Finance Director and became CEO in mid 2010, will hand over to Venables and leave the Company at the End of July.

02.07.2012 Dr. Christian Patermann, the mastermind behind the EU's bioeconomy strategy, has been honoured by the Accademia dei Georgofili in Florence. In a ceremony in the Uffizi at the end of April, Patermann was appointed as a member of the the first public association in Europe dedicated to agrarian studies.

As Programme Director Biotechnology, Agriculture and Food at DG Research of the European Commission, Patermann drafted the EU's knowledge-based bioeconomy plans.

Vorherige Seite2/6Nächste Seite


Current issue

All issues


All videos

Product of the week


Stock list

All quotes


  • THERAMETRICS (CH)0.06 CHF20.00%
  • PROTHENA PLC (IE)49.54 USD9.14%
  • BIOFRONTERA (D)2.27 EUR7.08%


  • BAVARIAN NORDIC (D)35.60 EUR-8.48%


  • CHRONTECH PHARMA (S)0.38 SEK3700.0%
  • THROMBOGENICS (B)3.84 EUR34.7%
  • OREXO (S)60.75 SEK22.2%


  • TRANSGENE (F)2.64 EUR-45.3%
  • GALAPAGOS (B)36.57 EUR-28.9%


  • KARO BIO (S)45.50 SEK4740.4%
  • CHRONTECH PHARMA (S)0.38 SEK375.0%
  • VERONA PHARMA (UK)4.55 GBP237.0%


  • NEOVACS (F)0.69 EUR-80.5%
  • BIOTEST (D)17.90 EUR-77.1%

No liability assumed, Date: 03.10.2015


All Events